-
Engineering a solution to high throughput COVID-19 virus testing in just nine days
SynbiCITE’s London BioFoundry acts on the WHO recommendation of ‘Test, Test, Test’ to show how throughput can be significantly increased. Re-thinking the approach to COVID-19 testing As lock-down around the world continues and the brightest and best biologists and clinicians accelerate efforts to develop a vaccine against the virus, immediate solutions are needed to slow…
-
Visbion Image Cubes deployed at NHS Nightingale Hospitals across the UK
Imaging critical to Covid-19 patient management and survival. Chertsey, Surrey, UK, 28th April 2020 / Sciad Newswire / As part of the NHS emergency response to Covid-19, Visbion’s Image Cube has been deployed at the new NHS Nightingale Hospitals in London, Birmingham and Harrogate. It is also being installed in over 150 existing mobile imaging trailers that can be deployed…
-
AskBio Acquires BrainVectis to Expand its Clinical Pipeline for Neurodegenerative Diseases
Research Triangle Park, N.C. and Paris, France, 22nd April 2020 / Sciad Newswire / Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that it has acquired BrainVectis, a Paris-based gene therapy company and French National Institute for Health and Medical Research (INSERM) spin-out with expertise and an intellectual property estate for the…
-
Solentim and ATUM to bundle Leap-In Transposase® with the VIPS™ single cell cloning instrument for cell line development
Bournemouth, UK and Newark, CA, USA, 20th April 2020 / Sciad Newswire / Solentim, a global leader in cell line development (CLD) instrumentation, and bioengineering company ATUM, today announced that Solentim will bundle access to the Leap-In Transposase® platform together with the Solentim VIPS™ single cell cloning instrument. Leap-In Transposases enable stable high titer clones to be…
-
MicrofluidX raises £1.4m in seed funding to develop novel cell therapy bioprocessing technology
London, UK, 20th April 2020 / Sciad Newswire / MicrofluidX announces it has raised £1.4m in seed funding from leading seed investors UK Innovation & Science Seed Fund (UKI2S), Longwall Ventures and Moulton Goodies Limited with angel contributions from 88 Capital and Cambridge Angels. The Company will develop its novel cell bioprocessing technology, utilising microfluidics to tackle…
-
Front-line and Community Initiative to Support the Correct Use of COVID-19 PPE
A team of doctors have launched a website to support UK NHS healthcare workers (and hopefully beyond) in their practical training in the correct use of COVID-19 Personal Protection Equipment. www.covid19ppe.org provides area relevant expert tuition and training on PPE COVID-19, provides a multiple choice question test (MCQ) regarding the correct use of PPE, as well as Objective…
-
Volunteer laboratory network launched to expand Covid-19 testing for key workers
The UK urgently needs to expand Covid-19 testing capacity for front-line healthcare workers There are thousands of laboratories in the UK with the right equipment and expertise to run these tests – but they are currently not being used SBL, a medical research laboratory in Oxfordshire, is already running 250-500 tests a week for local…
-
SwissDeCode is adapting its DNAFoil® technology to make more COVID-19 tests available within weeks
The world will never be the same again due to COVID-19, and the spread of the virus is showing little signs of slowing down. How long will it last, when will we know we’ve reached the peak and how can we avoid a second surge? These are the most challenging times many of us have…
-
Leading Korean pharmaceutical manufacturer transforms drug processing with Quantum 600 pump
Efficiency is essential at every stage in the production of medicines in order to minimise waste and bring medicines to patients more quickly. This results in more profitable organisations and greater means to invest in research and development. Minimising processing time is therefore an important consideration to optimise the design of a drug manufacturing process….
-
Check4Cancer’s Professor Gordon Wishart interviewed on Today Programme this morning
Professor Gordon Wishart, Chief Medical Officer and CEO at Check4Cancer, a leading early cancer detection and cancer prevention company, was interviewed on The Today Programme on BBC Radio 4 this morning, discussing the impact of the coronavirus pandemic on cancer diagnosis and treatment. Prof Wishart explained that patients with different types of cancer are experiencing delays…